UroGen Pharma (URGN) Common Equity (2016 - 2026)

UroGen Pharma (URGN) has reported Common Equity for 11 consecutive years, with -$124.3 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 167.45% year-over-year to -$124.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$124.3 million (down 167.45% YoY) and the FY2025 annual result came in at -$105.5 million, down 1098.16% from the prior year.
• Common Equity declined to -$124.3 million in Q1 2026 per URGN's latest filing, from -$105.5 million in the prior quarter.
• Over the last five years, Common Equity for URGN reached as high as $30.3 million in Q2 2024 and fell as low as -$138.4 million in Q2 2023.
• A 5-year average of -$61.8 million and a median of -$63.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity sank 1162.18% — and 2024, when it surged 160.76%.
• Year by year, Common Equity stood at -$89.4 million in 2022, then grew by 27.02% to -$65.2 million in 2023, then surged by 86.5% to -$8.8 million in 2024, then plunged by 1098.16% to -$105.5 million in 2025, then fell by 17.8% to -$124.3 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$124.3 million, -$105.5 million, and -$115.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.